Vioxx: lessons for Health Canada and the FDA
- 4 January 2005
- journal article
- Published by CMA Impact Inc. in CMAJ : Canadian Medical Association Journal
- Vol. 172 (1) , 5
- https://doi.org/10.1503/cmaj.045206
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Risk of cardiovascular events and rofecoxib: cumulative meta-analysisThe Lancet, 2004
- Rofecoxib (Vioxx) voluntarily withdrawn from marketCMAJ : Canadian Medical Association Journal, 2004
- Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treatCMAJ : Canadian Medical Association Journal, 2004
- Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach.2003